Bristol Myers Squibb has partnered with Anthropic to deploy Claude as an enterprise-wide AI platform, aiming to accelerate drug discovery and operational efficiency. This strategic agreement marks a significant evolution in the company's digital strategy, building on over three years of AI investment.
- The collaboration will embed advanced agentic capabilities across research, clinical development, manufacturing, and commercial functions to move beyond conversational AI.
- Bristol Myers Squibb shares closed at $58.31 (up 1.74%) on May 19, with pre-market activity showing limited immediate reaction to the news on May 20.